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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1733Ventricular Arrhythmias in Patients With Structurally Normal HeartsEric N. Prystowsky, Benzy J. Padanilam, Sandeep Joshi, Richard I. Fogel
Ventricular arrhythmias (VAs) in structurally normal hearts can be broadly considered under
nonlife-threatening monomorphic and life-threatening polymorphic rhythms. Monomorphic
VAs are classified based on the site of origin, and the most common areas are the ventricular
outflow tracts and left ventricular fascicles. Polymorphic ventricular tachycardia (VT) is rare
and the result of an ion channel disorder including long QT syndrome, Brugada syndrome,
catecholaminergic polymorphic VT, and short QT syndrome. These syndromes are associated
with sudden death although identifying which patients are likely to benefit from primary
prevention with a defibrillator remains challenging.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY
1745Significantly Worse Outcomes in ACS Patients With
intraprocedural Thrombotic Events During PCIMargaret B. McEntegart, Ajay J. Kirtane, Ecaterina Cristea Sorin Brener, Roxana Mehran, Martin Fahy,
Jeffrey W. Moses, Gregg W. Stone
McEntegart and colleagues performed a detailed frame-by-frame core lab angiographic
analysis of subjects enrolled in the ACUITY trial to determine the frequency and prognostic
significance of intraprocedural thrombotic events (IPTE). An IPTE, defined as the
development of new or increasing thrombus, abrupt vessel closure, no reflow, slow reflow, or
distal embolization occurred in 3.5% of subjects. Patients with IPTE had higher in-hospital,
30-day, and 1-year major adverse cardiovascular events rates than patients without IPTE.
Unplanned revascularization, target vessel revascularization, and noncoronary artery bypass
graft surgery major bleeding were also increased in patients with IPTE. These results show
that IPTE significantly increases the risk of subsequent adverse outcomes including death,
myocardial infarction, and stent thrombosis.(continued on page A-18)
MAY 15, 2012 (continued) A-18INTERVENTIONAL CARDIOLOGY1752Higher Mortality for In-Hospital Than Out-of-Hospital Stent ThrombosisGeorge D. Dangas, Bimmer E. Claessen, Roxana Mehran, Sorin Brener, Bruce R. Brodie, Dariusz Dudek,
Bernhard Witzenbichler, Jan Z. Peruga, Giulio Guagliumi, Jeffrey W. Moses, Alexandra J. Lansky, Ke Xu,
Gregg W. Stone
Dangas and colleagues used data from the HORIZONS-AMI trial to determine if rapid
access to medical care and reperfusion results in a better prognosis in patients with in-hospital
compared to out-of-hospital stent thrombosis (ST) after ST-segment elevation myocardial
infarction. A total of 3,602 patients who underwent primary percutaneous coronary
intervention were followed and 4.9% developed Academic Research Consortium definite/
probable ST during 3-years of follow-up. The mortality was significantly higher in those with
in-hospital compared to out-of-hospital ST (28% vs. 11%). Patients with in-hospital ST also
had higher rates of major bleeding. These results show that following primary percutaneous
coronary intervention, more than one-third of all ST events occurred during the index
hospitalization with significant morbidity and mortality.Editorial Comment: Lloyd W. Klein, Carlos Arrieta-Garcia, page 1760CARDIOVASCULAR RISK
1763Genetic Variation in ANP Gene Linked
to Risk of Subsequent Myocardial InfarctionEmanuele Barbato, Jozef Bartunek, Fabio Mangiacapra, Sebastiano Sciarretta, Rosita Stanzione, Leen Delrue,
Maria Cotugno, Simona Marchitti, Guido Iaccarino, Giusy Sirico, Sara Di Castro, Anna Evangelista,
Diether Lambrechts, Peter Sinnaeve, Bernard De Bruyne, Frans Van De Werf, Stefaan Janssens,
Keith A. A. Fox, William Wijns, Massimo Volpe, Speranza Rubattu
Barbato and colleagues investigated whether the rs5065 atrial natriuretic peptide (ANP) gene
variant affects outcomes in subjects with coronary artery disease (CAD). This ANP variant is
present in 14% to 23% of individuals, and the resultant, a mutant peptide, may induce
endothelial cell damage by increasing reactive oxygen species production. Subjects undergoing
coronary angiography for suspected CAD were genotyped for the rs5065 ANP gene variant,
including an initial and a replication cohort. The rs5065 minor allele was an independent
predictor of presenting with an acute coronary syndrome and, during follow-up, was
independently associated with a higher rate of major adverse cardiovascular events (MACE).
These results suggest that this genetic variant in the ANP gene increases the risk of plaque
rupture in patients with CAD.(continued on page A-19)
MAY 15, 2012 (continued) A-19CARDIOVASCULAR RISK1771Sex Differences in Cardiovascular Risk: Role of Pulse Pressure AmplificationVéronique Regnault, Frédérique Thomas, Michel E. Safar, Mary Osborne-Pellegrin, Raouf A. Khalil,
Bruno Pannier, Patrick Lacolley
Regnault and colleauges used data from over 100,000 subjects to study the relationship
between sex and the prognostic value of the brachial/carotid pulse pressure (B/C-PP) ratio.
C-PP is usually lower than B-PP, but the difference diminishes with age as aortic stiffness
tends to increase. C-PP was calculated for over 100,000 subjects and subjects were followed
for a mean of 12 years. Men 55 years of age had the highest mean B/C ratio (1.56) while
older women had the lowest (1.16) mean B/C ratio. The adjusted hazard ratios (HR)
associated with a 1-SD decrease from the mean in the B/C-PP ratio for all-cause mortality
was 1.51 in men and 2.46 in women. After adjustment for multiple risk risk factors, a
decrease in PP amplification of 1 SD was associated with an increase of 81% for
cardiovascular mortality in men, while in women the increase was 346%. These results
suggest that in women, the attenuation of PP amplification related to increased aortic stiffness
contributes to a significant increase in cardiovascular risk.CARDIOVASCULAR RISK1778PCSK9 Levels, Statin Therapy, and Clinical OutcomesRoeland Huijgen, S. Matthijs Boekholdt, Benoit J. Arsenault, Weihang Bao, Jean-Michel Davaine,
Fatiha Tabet, Francine Petrides, Kerry-Anne Rye, David A. DeMicco, Philip J. Barter, John J. P. Kastelein,
Gilles Lambert
Statins activate low-density lipoprotein (LDL) receptor gene expression, but also increase the
expression of proprotein convertase subtilisin kexin type 9 (PCSK9), a secreted inhibitor of
the LDL receptor. Huijgen and colleagues investigated whether high levels of circulating
PCSK9 were associated with higher cardiovascular risk in statin-treated patients. Plasma
PCSK9 levels were measured in a subset of patients enrolled in the TNT study. After a
run-in period with atorvastatin 10 mg/day, patients were randomized to either 10 mg or 80
mg. Circulating PCSK9 levels measured at randomization, while on 10 mg, predicted clinical
outcomes in those who remained on atorvastatin 10 mg, but not in those who intensified
atorvastatin treatment to 80 mg.(continued on page A-20)
MAY 15, 2012 (continued) A-20HEART FAILURE1785Higher Heart Rate Linked to Worse Outcomes in Patients With Chronic HFDavide Castagno, Hicham Skali, Madoka Takeuchi, Karl Swedberg, Salim Yusuf, Christopher B. Granger,
Eric L. Michelson, Marc A. Pfeffer, John J. V. McMurray, Scott D. Solomon, for the CHARM Investigators
Castagno and colleagues explored the relationship between baseline resting heart rate and
outcomes in patients with chronic heart failure (HF) according to baseline left ventricular
ejection fraction (LVEF) and cardiac rhythm. Subjects enrolled in the CHARM trials were
divided into tertiles of baseline heart rate. After adjusting for predictors of poor prognosis,
patients in the highest heart rate tertile had worse outcomes when compared with those in
the lowest. When modeling heart rate as a linear continuous variable, a 10-beat increase in
heart rate was associated with an 8% increase in the risk of death, with similar results across
LVEF categories and beta-blocker use. These results confirm that resting heart rate is an
important predictor of outcome in patients with stable chronic HF without atrial fibrillation.Editorial Comment: Jonathan G. Howlett, page 1796CARDIAC IMAGING17993DE Compared to CMR and Standard Echocardiography for Measuring LV VolumesJennifer L. Dorosz, Dennis C. Lezotte, David A. Weitzenkamp, Larry A. Allen, Ernesto E. Salcedo
Dorosz and colleagues performed a systematic review to objectively evaluate the performance
of three-dimensional echocardiography (3DE) in measuring left ventricular (LV) volumes and
ejection fraction (EF). Studies that compared LV volumes and EF measured by 3DE and
cardiac magnetic resonance (CMR) imaging were reviewed. A subset of those also
compared standard 2D methods to CMR. There was a consistent trend that 3DE
underestimated end-diastolic volume and end systolic volume by 19 ml and 10 ml.
Compared to 2-dimensional echocardiography (2DE), the volumes were also measured
lower with 3DE by 48 ml and 28 ml. The differences in EF were 0.6% and 0.1%. 3DE
underestimates volumes compared to 2DE and CMR, but is closer than 2DE to CMR,
which is considered the gold standard.
